Advised and represented a leading pharmaceutical company, in a high-stakes arbitration before the London Court of International Arbitration instituted by HDT Bio Corp. (“HDT”), a US-based private company engaged in development of RNA vaccine products. HDT claimed that the company had allegedly breached the License Agreement by creating a Covid-19 vaccine without involving HDT and without any payment of royalties using Lipid Iron Oxide Nanoparticle or Lipid Inorganic Nanoparticle (“LION”), a form of cationic nano-emulsion (“CNE”) technology developed by HDT. The dispute was highly complex, involving intricate arguments on biotechnology and intellectual property. In addition, Parinam also acted as instructing attorneys in proceedings before United States District Court for Western District of Washington for alleged violation of trade secrets. The case involved the deposition of witnesses in India through U.S. court proceedings, leading to the issuance of unopposed Letters Rogatory. Parinam advised and conducted the deposition of the witnesses in India in relation to the US proceedings. Ultimately, the arbitration reached a favourable resolution through an amicable settlement between the parties.
